Traders Purchase Large Volume of Agenus Call Options (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN) was the recipient of unusually large options trading activity on Monday. Investors bought 9,107 call options on the company. This represents an increase of approximately 2,764% compared to the typical volume of 318 call options.

Agenus Stock Up 107.4%

NASDAQ:AGEN traded up $3.60 on Monday, reaching $6.95. The stock had a trading volume of 129,233,903 shares, compared to its average volume of 1,710,650. The company has a market capitalization of $289.36 million, a P/E ratio of 4.52 and a beta of 1.55. Agenus has a 1-year low of $2.71 and a 1-year high of $8.70. The stock has a fifty day moving average price of $3.31 and a 200-day moving average price of $3.42.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Monday, May 11th. The biotechnology company reported $1.02 earnings per share for the quarter, missing the consensus estimate of $2.10 by ($1.08). The firm had revenue of $33.74 million for the quarter, compared to analyst estimates of $129.50 million. Agenus had a negative return on equity of 31.66% and a net margin of 50.49%. Sell-side analysts predict that Agenus will post 0.02 earnings per share for the current fiscal year.

Institutional Trading of Agenus

Several large investors have recently made changes to their positions in AGEN. Bank of America Corp DE increased its stake in shares of Agenus by 796.7% in the first quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock valued at $397,000 after buying an additional 105,536 shares in the last quarter. Redwood Family Wealth LLC acquired a new position in Agenus during the 4th quarter worth about $44,000. Ovata Capital Management Ltd bought a new stake in Agenus during the 4th quarter worth about $97,000. Virtu Financial LLC bought a new stake in Agenus during the 4th quarter worth about $108,000. Finally, EP Wealth Advisors LLC acquired a new stake in Agenus in the 4th quarter valued at about $31,000. Institutional investors own 61.46% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Wall Street Zen raised Agenus from a “hold” rating to a “buy” rating in a report on Monday, April 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agenus in a research note on Tuesday, June 16th. Finally, Zacks Research cut Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Agenus has a consensus rating of “Hold” and a consensus target price of $23.00.

Agenus News Roundup

Here are the key news stories impacting Agenus this week:

• Positive Sentiment: Agenus entered an oversubscribed private placement that brings in about $85 million upfront, with up to $255 million more possible if warrants are exercised, giving the company a potential $340 million total financing package. Article Title
• Positive Sentiment: The new funding is intended to support the registrational Phase 3 ROBBIN trial of botensilimab plus balstilimab in MSS colon cancer, which investors may view as a clearer and more valuable development path. Article Title
• Neutral Sentiment: Management said the cash runway could extend into 2027 even without warrant exercise, and potentially longer if the warrants are fully exercised, reducing near-term financing risk. Article Title
• Neutral Sentiment: Agenus also said it plans to stop funding the BATTMAN metastatic colorectal cancer study, signaling a strategic pivot away from that program and toward ROBBIN. Article Title
• Negative Sentiment: The BATTMAN cutback could be seen as a sign of prioritization under financial constraints, and the company still depends on future clinical progress to justify the sharp share-price jump. Article Title

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.